BioSpace News Archive

Companion diagnostics will be developed to identify patients with NSCLC that harbor ALK fusions and EGFR Exon20 insertion mutations to match patients with appropriate targeted therapies from Takeda

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, presented additional results from its pivotal Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously treated non-small cell lung cancer patients with HER2 exon 20 insertion mutations.

Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

Medimetriks Pharmaceuticals, Inc. today announced that the Company received a Type C Meeting Written Response from the U.S. Food and Drug Administration (FDA) regarding MM36 (difamilast) for the topical treatment of mild to moderate atopic dermatitis (AD).

StageZero Life Sciences, Ltd (TSX:SZLS) (“StageZero” or the “Corporation”) announced that trading of the common shares on the TSX on a post-Consolidation basis commences at market open on September 18, 2020.

Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the promotion of Gregory S. Wessels to the newly created position of Chief Commercial Officer

Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Trodelvy delivered 150-fold and 40-fold the 50% inhibitory concentration (IC50) of SN-38 for BMBC and rGBM, respectively, and produced partial responses in both cohorts of brain cancer patients.

The ongoing COVID-19 pandemic is projected to generate prominent sales avenues in the global vaccine glass bottle market during the tenure of 2019 to 2029.

Urine drainage bags are used for urine collection. This bag is attached to sheath or catheter that is inside the bladder of an individual.